InsiderDB
Sign inStart free trial

Viatris (VTRS)

Healthcare · Drug Manufacturers - Specialty & Generic

6 members of Congress have disclosed 11 trades in Viatris (VTRS) since 2020: 4 buys and 7 sales. The most recent was disclosed on Dec 15, 2025.

Trades disclosed
11
Members trading
6
Buys / sells
4 / 7
Reported value
$11K–$165K

Keep following the company.

Subscribers get new congressional filings and notable insider purchases for companies they follow. Coverage varies by company.

Follow VTRS

What else is happening at VTRS

All research →

Company filings and public records connected to this stock, ordered by when they became public or were first observed.

  1. VTRSLobbying report·Lobbying disclosures

    VTRS: third_quarter 2026 lobbying report

    S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages S. 2658, The Medication Affordability and Patent Integrity Act IP Issues related to generic medicines Patent Settlements Trade issues related to generic medicines Pharmaceutical supply chain S.3778: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act S.3841: Last Sale Valuation Act Policy related to corporate

    Public: Oct 20, 2026, 8:43 PM EDTOriginal source ↗
  2. VTRSLobbying report·Lobbying disclosures

    VTRS: third_quarter 2026 lobbying report

    Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations and National Defense Authorization Act (S. 1071). Trade issues related to generic medicines.

    Public: Oct 19, 2026, 4:20 PM EDTOriginal source ↗
  3. VTRSLobbying report·Lobbying disclosures

    VTRS: third_quarter 2026 lobbying report

    S. 1302 - Increasing Transparency in Generic Drug Applications Act; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; Drug Shortages; Medicaid Generics Penalty.

    Public: Oct 7, 2026, 6:43 AM EDTOriginal source ↗
  4. VTRSLobbying report·Lobbying disclosures

    VTRS: second_quarter 2026 lobbying report

    S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages S. 2658, The Medication Affordability and Patent Integrity Act IP Issues related to generic medicines Patent Settlements Trade issues related to generic medicines Pharmaceutical supply chain S.3778: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act S.3841: Last Sale Valuation Act Policy related to corporate

    Public: Jul 20, 2026, 8:26 PM EDTOriginal source ↗
  5. VTRSLobbying report·Lobbying disclosures

    VTRS: second_quarter 2026 lobbying report

    Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations and National Defense Authorization Act (S. 1071). Trade issues related to generic medicines.

    Public: Jul 20, 2026, 2:51 PM EDTOriginal source ↗

Who traded VTRS

All trades

From periodic transaction reports filed under the STOCK Act. Amounts are the ranges members report, and trades can be disclosed up to 45 days after they happen. Nothing here is investment advice.